3 New FDA Approvals for Blood Cancers

Foundation announces grants in the amount of $1,531,500

In the fall of 2015, the FDA approves three new treatments—daratumumab (Darzalex), elotuzumab (Empliciti) and ixazomib (Ninlaro)—that activate the body’s immune system to attack multiple myeloma cells or hinder their ability to grow.